恶性:当前的治疗选择和治疗前景
Julia M Berger1, Matthias Preusser1, Anna S Berghoff1
1Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Personalized Immunotherapy, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
恶性炎 (MA),癌症患者的液体积累,是一个临床挑战. 新的研究探索了它的病理生理学,包括免疫系统的参与,以改善患者的治疗和生存.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 恶性炎 (MA) 是一种常见的癌症并发症,导致患者患病率显著,存活率降低.
- 目前针对MA的治疗方法,主要是针对原发性瘤和液体排水,由于不完全了解病理生理学,其疗效有限.
- 已确定的原因包括淋巴阻塞和血管内皮生长因子 (VEGF),新出现的证据涉及腹腔内免疫系统.
研究的目的:
- 审查关于恶性瘤病理生理学的当前知识.
- 总结现有和新的治疗策略,MA和准恶性.
- 识别知识差距和未来的研究方向,以改善MA管理.
主要方法:
- 关于恶性炎的当前研究的文献综述.
- 分析病理生理机制,包括瘤细胞参与和免疫反应.
- 对MA和准恶性炎的治疗方法的评估.
主要成果:
- MA的特征是瘤细胞在瘤中,导致发病率和死亡率.
- 准恶性炎涉及流体积累,没有可检测的瘤细胞.
- 对MA病理生理学中的免疫系统作用的新见解正在出现.
结论:
- 更深入地了解MA病理生理学对于开发有效的致病疗法至关重要.
- 对新型机制的进一步研究,特别是免疫系统的参与,有望为未来的治疗改进提供希望.
- 解决知识差距对于推进恶性炎的临床管理至关重要.
更多相关视频
09:02Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
07:44Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
Published on: March 25, 2022
相关概念视频
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Chronic Pancreatitis II: Collaborative Care
Assessment:
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Acute Pancreatitis II: Clinical Manifestations and Management
